What is the official website of Fresenius Kabi Asia Pacific ?

The official website of Fresenius Kabi Asia Pacific is http://www.fresenius-kabi.com.

What is Fresenius Kabi Asia Pacific's cybersecurity risk score?

Fresenius Kabi Asia Pacific has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Fresenius Kabi Asia Pacific experienced?

According to Rankiteo, Fresenius Kabi Asia Pacific currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Fresenius Kabi Asia Pacific been affected by any supply chain cyber incidents ?

According to Rankiteo, Fresenius Kabi Asia Pacific has been affected by a supply chain cyber incident involving Fresenius Kabi USA, with the incident ID FRE1781735374.

Does Fresenius Kabi Asia Pacific have SOC 2 Type 1 certification ?

According to Rankiteo, Fresenius Kabi Asia Pacific is not certified under SOC 2 Type 1.

Does Fresenius Kabi Asia Pacific have SOC 2 Type 2 certification ?

According to Rankiteo, Fresenius Kabi Asia Pacific does not hold a SOC 2 Type 2 certification.

Does Fresenius Kabi Asia Pacific comply with GDPR ?

According to Rankiteo, Fresenius Kabi Asia Pacific is not listed as GDPR compliant.

Does Fresenius Kabi Asia Pacific have PCI DSS certification ?

According to Rankiteo, Fresenius Kabi Asia Pacific does not currently maintain PCI DSS compliance.

Does Fresenius Kabi Asia Pacific comply with HIPAA ?

According to Rankiteo, Fresenius Kabi Asia Pacific is not compliant with HIPAA regulations.

Does Fresenius Kabi Asia Pacific have ISO 27001 certification ?

According to Rankiteo,Fresenius Kabi Asia Pacific is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Fresenius Kabi Asia Pacific operate in ?

Fresenius Kabi Asia Pacific operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Fresenius Kabi Asia Pacific have ?

Fresenius Kabi Asia Pacific employs approximately 143 people worldwide.

Does Fresenius Kabi Asia Pacific own any subsidiaries ?

Fresenius Kabi Asia Pacific presently has no subsidiaries across any sectors.

How many LinkedIn followers does Fresenius Kabi Asia Pacific have ?

Fresenius Kabi Asia Pacific's official LinkedIn profile has approximately 13,731 followers.

Does Fresenius Kabi Asia Pacific have a Crunchbase profile ?

No, Fresenius Kabi Asia Pacific does not have a profile on Crunchbase.

Does Fresenius Kabi Asia Pacific have a LinkedIn profile ?

Yes, Fresenius Kabi Asia Pacific maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/freseniuskabi-apac.

How many cybersecurity incidents has Fresenius Kabi Asia Pacific experienced ?

As of July 22, 2026, Rankiteo reports that Fresenius Kabi Asia Pacific has experienced 3 cybersecurity incidents.

How many peer or competitor companies does Fresenius Kabi Asia Pacific have ?

Fresenius Kabi Asia Pacific has an estimated 5,710 peer or competitor companies worldwide.

What types of cybersecurity incidents has Fresenius Kabi Asia Pacific faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FKAP

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Fresenius Kabi Asia Pacific Vendor Cyber Rating & Cyber Score

fresenius-kabi.com

Add Your Compliance Badge

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. Fresenius Kabi employs about 35,000 people worldwide. In 2016 the company reported sales of more than €6 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group. Fresenius Kabi is a global leader in our business segments. We offer

FKAP A.I CyberSecurity Scoring

Scoring History

FKAP

Fresenius Kabi Asia Pacific CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Fresenius Kabi USA

Breach

100

1/2026

Fresenius Kabi ...

FRE1781735374

Fresenius Group

Ransomware

100

5/2020

FRE1770566194

Fresenius Kabi Asia...

Ransomware

05/2020

FRE2038291222

Loading…

A.I.

FKAP Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FKAP

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Asia Pacific in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Fresenius Kabi Asia Pacific in 2026.

Incident Types FKAP vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Asia Pacific in 2026.

Incident History - FKAP (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Fresenius Kabi Asia Pacific Subsidiaries

FKAP

Pharmaceutical Manufacturing

Website: http://www.fresenius-kabi.com

Company Size: 143

Fresenius KabiPharmaceutical Manufacturing

Fresenius GroupHospitals and Health Care

Fresenius Digital TechnologyInformation Technology & Services

Fresenius Investor RelationsKrankenhäuser und Gesundheitseinrichtungen

Helios Health GmbHHospitals and Health Care

QuirónsaludWellness and Fitness Services

Helios Kliniken GmbHHospitals and Health Care

Fresenius Kabi BrasilPharmaceutical Manufacturing

Fresenius Kabi USAPharmaceutical Manufacturing

Fresenius Kabi FrancePharmaceutical Manufacturing

Fresenius Kabi CanadaPharmaceutical Manufacturing

Fenwal, Inc., a Fresenius Kabi CompanyMedical Equipment Manufacturing

Fresenius Kabi ColombiaPharmaceutical Manufacturing

Fresenius Kabi UKPharmaceutical Manufacturing

MOTIV eLearningHospitals and Health Care

Fresenius Kabi ArgentinaPharmaceutical Manufacturing

Fresenius Kabi EspañaPharmaceutical Manufacturing

Fresenius Kabi EcuadorPharmaceutical Manufacturing

Fresenius Kabi ChilePharmaceutical Manufacturing

Fresenius Kabi PortugalPharmaceutical Manufacturing

Fresenius Kabi EuropePharmaceutical Manufacturing

Fresenius Kabi ItaliaPharmaceutical Manufacturing

Fresenius Kabi MedTech EuropeMedical Equipment Manufacturing

Fresenius Kabi Australia and New ZealandPharmaceutical Manufacturing

Fresenius Kabi AustriaPharmaceutical Manufacturing

Fresenius Kabi Business ServicesAccounting

Fresenius Kabi PolskaPharmaceutical Manufacturing

Fresenius Kabi DanmarkPharmaceutical Manufacturing

Fresenius Kabi South AfricaPharmaceutical Manufacturing

Fresenius Kabi NetherlandsPharmaceutical Manufacturing

Fresenius Kabi IrelandPharmaceutical Manufacturing

Fresenius Kabi Viet Nam Pharmaceutical Manufacturing

Fresenius Kabi BelgiumPharmaceutical Manufacturing

Fresenius Kabi SchweizPharmaceutical Manufacturing

Fresenius Kabi (Singapore) Pte Ltd, SingaporePharmaceutical Manufacturing

Fresenius Kabi Puerto RicoManufacturing

Fresenius Kabi MéxicoPharmaceutical Manufacturing

Unidos por la Nutrición Clínica MéxicoHospitals and Health Care

Loading…

Fresenius Kabi Asia Pacific Similar Companies

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Loading…

NEWS

Fresenius Kabi Asia Pacific CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-63261

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-72/388575

CVE-2026-63260

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-71/388574

CVE-2026-63259

SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-9-4-4-security-update-esa-2026-70/388573

CVE-2026-63145

SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-19-9-3-8-9-4-4-security-update-esa-2026-69/388572

CVE-2026-63144

SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

Published

Date2026-07-21

Updated

Date2026-07-21

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-19-9-3-8-9-4-4-security-update-esa-2026-68/388571

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…